Group 1 - The core point of the article highlights the recent decline in the stock price of New Nuo Wei, which fell by 5.36% to 37.44 CNY per share, with a trading volume of 245 million CNY and a turnover rate of 0.46%, resulting in a total market capitalization of 52.588 billion CNY [1] - New Nuo Wei, officially known as Shiyao Innovation Pharmaceutical Co., Ltd., is based in Shijiazhuang, Hebei Province, and was established on April 5, 2006. The company went public on March 22, 2019, and its main business involves the research, development, production, and sales of functional foods [1] - The revenue composition of New Nuo Wei is primarily from functional foods and raw materials at 88.93%, followed by biopharmaceuticals at 8.91%, and other sources at 2.16% [1] Group 2 - From the perspective of major fund holdings, data indicates that a fund under Jianxin Fund has a significant position in New Nuo Wei. Jianxin Medical Health Industry Stock A (008923) increased its holdings by 590,300 shares in the third quarter, bringing the total to 1.4473 million shares, which constitutes 4.74% of the fund's net value, ranking it as the seventh-largest holding [2] - Jianxin Medical Health Industry Stock A (008923) was established on December 28, 2021, with a current scale of 702 million CNY. Year-to-date returns are at 41.64%, ranking 1006 out of 4197 in its category; over the past year, returns are 40.12%, ranking 959 out of 4179; and since inception, returns are 39.64% [2]

北京海润天睿律师事务所 关于石药创新制药股份有限公司 2025 年第三次临时股东会的法律意见书 北京市朝阳区建外大街甲 14 号广播大厦 5 层/9 层/10 层/13 层/17 层 电话：010-65219696 传真：010-88381869 法律意见书 北京海润天睿律师事务所 关于石药创新制药股份有限公司 1. 在本法律意见书中，本所及本所律师仅就本次股东会的召集及召开程序、 出席会议人员及召集人的资格、表决程序及表决结果进行核查和见证并发表法律 意见，不对本次股东会的议案内容及其所涉及的事实和数据的完整性、真实性和 准确性发表意见。 2. 本所及本所律师依据《证券法》《律师事务所从事证券法律业务管理办 法（2023）》和《律师事务所证券法律业务执业规则（试行）》等规定以及本法 律意见书出具日以前已经发生的或者存在的事实，严格履行了法定职责，遵循了 勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本法律意见书所认定的 事实真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误 导性陈述或者重大遗漏，并对此承担相应法律责任。 3. 公司已向本所及本所律师保证并承诺，其所发布或提供的与本次股东 ...

证券代码：300765 证券简称：新诺威 公告编号：2025-102 石药创新制药股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1. 本次股东会未出现否决议案的情形。 2. 本次股东会不涉及变更以往股东会已通过的决议的情形。 一、会议的召开和出席情况 1. 股东会的届次：2025 年第三次临时股东会。 2. 会议召集人：公司董事会。 3. 会议主持人：公司董事长姚兵。 4. 会议召开的日期、时间： （1）现场会议召开时间：2025 年 12 月 25 日（星期四）下午 14:30 开始。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 12 月 25 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交 易所互联网投票系统投票的具体时间为：2025 年 12 月 25 日 9:15-15:00。 5. 现场会议召开地点：河北省石家庄市高新区中山东路 896 号公司会议室。 通过网络投票的股东 377 人，代表股份 123,5 ...

Core Viewpoint - The announcement indicates that the company’s subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of Daratumumab injection, a biosimilar to the original drug, targeting multiple myeloma patients [1] Group 1 - The clinical trial approval notification for Daratumumab injection was recently issued [1] - Daratumumab injection is a recombinant fully human IgG1 monoclonal antibody targeting ADP-ribosyl cyclase (CD38) [1] - The drug is classified as a biosimilar to the original drug, Zhaoke®, and is submitted under category 3.3 for therapeutic biological products [1] Group 2 - The drug is intended for the treatment of adult patients with multiple myeloma [1]

Group 1 - Shareholder of Okoyi plans to reduce holdings by up to 1.89% of the company's shares, amounting to a maximum of 3 million shares due to personal funding needs [1] - Tianchuang Fashion is planning a change in control, leading to continued suspension of its stock trading, expected to last no more than 3 trading days [2] - China Electric Power Construction Company reported a new contract amount of 10,317.55 billion yuan for the first 11 months of 2025, a year-on-year decrease of 1.65% [3] Group 2 - Pilin Bio's wholly-owned subsidiary received approval for a clinical trial of a drug, indicating progress in its product development [4] - Yihong Medical obtained two medical device registration certificates for diagnostic kits, enhancing its product portfolio [5] - Aohong Electronics plans to use up to 450 million yuan of idle fundraising for cash management, targeting safe and liquid financial products [6] Group 3 - China Electric Power Construction signed a contract worth approximately 6.626 billion yuan for a natural gas booster station project in Turkey, with a construction period of about 55 months [7] - Baosheng Co. won a bid for a power cable project in Singapore, valued at around 1.2 billion yuan, marking the largest overseas order in its history [8] - *ST Xinyan's stock will resume trading on December 24, 2025, following a capital increase plan that will raise its total share capital to 3.29 billion shares [9] Group 4 - Ningbo Construction's subsidiary signed a construction contract worth 428 million yuan for an engineering project with a duration of 990 days [11] - Lianhuan Pharmaceutical's subsidiary received approval for a drug that passed the consistency evaluation for generic drugs, enhancing its market competitiveness [12] - Zhongjie Automotive received a project designation for a new electric air conditioning compressor, with expected sales of approximately 29.86 million USD over its lifecycle [13] Group 5 - Biopharmaceuticals' major shareholder plans to increase holdings by 50 million to 100 million yuan, indicating confidence in the company's future [14] - Haizheng Pharmaceutical's subsidiary received approval for a veterinary drug product, expanding its product offerings in the animal health sector [15] - *ST Songfa's subsidiary signed contracts for the construction of 8 vessels, with a total contract value between 200 million to 400 million USD [16] Group 6 - Shandong Pharmaceutical Glass announced the resignation of its chairman due to age reasons, indicating a potential leadership transition [17] - Xinno Wei's subsidiary received approval for a clinical trial of a monoclonal antibody drug, indicating advancements in its drug development pipeline [18] - Ningbo Huaxiang's subsidiary secured an order for robot joints, expected to positively impact future business performance [19][20] Group 7 - China Resources Double Crane's subsidiary received approval for a clinical trial of a drug aimed at treating a genetic eye disease, reflecting ongoing R&D efforts [21] - Huaxin Technology's shareholders set a transfer price of 56.69 yuan per share for a block of shares, indicating active shareholder engagement [22] - Xinhua Net announced the resignation of its president due to job relocation, suggesting potential changes in management [23] Group 8 - Taiji Group plans to transfer a 40% stake in a subsidiary to focus on its core pharmaceutical business, enhancing operational efficiency [24] - Huaxin Construction's shareholder plans to increase holdings by 200 million to 400 million yuan, reflecting confidence in the company's prospects [25] - Dongjie Intelligent is planning to issue shares and cash for asset acquisition, with stock trading suspended until further notice [26] Group 9 - Wanrun New Energy was designated as a delivery warehouse for lithium carbonate futures, indicating its strategic position in the market [27] - Prolo Pharmaceutical's subsidiary received a drug registration certificate for an influenza treatment, expanding its product range [28] - Saiwu Technology invested 5 million yuan in a private equity fund focused on smart vehicles and energy innovation, indicating strategic investment in growth sectors [29] Group 10 - Bohui Innovation's subsidiary received approval for a clinical trial of an immunoglobulin drug, indicating progress in its product development [30] - Bohui Innovation's subsidiary also received a drug registration certificate for a coagulation factor product, enhancing its therapeutic offerings [31] - Hanghua Co. plans to allocate 146 million yuan of surplus fundraising for a new green printing materials project, reflecting a commitment to sustainability [32] Group 11 - Nova Star Cloud obtained a loan commitment letter from a bank for a share repurchase plan, indicating financial support for its capital management strategy [33] - Jimin Health established a joint venture for technology innovation, indicating a strategic move to enhance its technological capabilities [34] - Huili Pharmaceutical received a drug registration certificate for a medication used in treating digestive ulcers, expanding its product portfolio [35]

Core Viewpoint - The company XinNuoWei (300765.SZ) announced that its subsidiary, Giant Stone Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of Daratumumab injection, a biosimilar to the original drug, targeting multiple myeloma patients [1] Group 1 - The clinical trial approval notification for Daratumumab injection has been issued, allowing the company to commence clinical trials shortly [1] - Daratumumab injection is a recombinant fully human IgG1 monoclonal antibody that targets ADP-ribosyl cyclase (CD38) [1] - The drug is classified as a Class 3.3 biological product for therapeutic use and is intended for adult patients with multiple myeloma [1]

达雷妥尤单抗注射液是一种靶向ADP-核糖基环化酶(CD38)的重组全人源IgG1单克隆抗体，为原研药兆 珂的生物类似药，按照治疗用生物制品3.3类申报，适用于治疗多发性骨髓瘤成年患者。该产品研发遵 循生物类似药相关研究指导原则，药学及非临床研究结果显示，该产品与原研参照药在质量、安全性和 有效性方面高度相似，支持开展后续临床研究。 新诺威（300765）(300765.SZ)发布公告，公司的控股子公司石药集团巨石生物制药有限公司(以下简 称"巨石生物")于近日收到国家药品监督管理局核准签发的关于达雷妥尤单抗注射液的《药物临床试验 批准通知书》，将于近期开展临床试验。 ...

Core Viewpoint - The announcement indicates that the company’s subsidiary, Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of Daratumumab injection, a biosimilar to the original drug, targeting multiple myeloma patients [1] Group 1 - The clinical trial approval is for Daratumumab injection, a recombinant fully human IgG1 monoclonal antibody targeting ADP-ribosyl cyclase (CD38) [1] - The product is classified as a biosimilar to the original drug, known as Zhaoke®, and is submitted under the category of biological products for therapeutic use [1] - The research results indicate that the biosimilar shows high similarity in quality, safety, and efficacy compared to the reference drug, supporting the initiation of subsequent clinical studies [1]

Core Viewpoint - The company XinNuoWei (300765.SZ) announced that its subsidiary, JuShi Bio, has received approval from the National Medical Products Administration for the clinical trial of Daratumumab injection, a biosimilar to the original drug, which is intended for the treatment of adult patients with multiple myeloma [1] Group 1 - The clinical trial approval notification allows the company to proceed with clinical trials for the drug [1] - Daratumumab is a biosimilar of the original drug, known as Zhaoke® [1] - The drug is specifically aimed at treating adult patients diagnosed with multiple myeloma [1] Group 2 - Following the approval, the drug must undergo clinical trials and receive further approval from regulatory authorities before it can be marketed and sold [1] - There are inherent risks associated with the clinical trial process, including the possibility of trial results not meeting expectations, failure to obtain necessary approvals, delays in market entry, or lower-than-expected sales post-launch [1]

Core Viewpoint - The announcement indicates that the subsidiary of XinNuoWei, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of Daratumumab injection, a biosimilar to the original drug, which is intended for the treatment of adult patients with multiple myeloma [1] Group 1 - The clinical trial approval notification for Daratumumab injection has been issued, allowing the company to commence clinical trials shortly [1] - Daratumumab injection is a recombinant fully human IgG1 monoclonal antibody targeting ADP-ribosylation factor (CD38) [1] - The drug is a biosimilar to the original drug, Zhaoke®, which is used for treating multiple myeloma [1]